PRODUCTS

Minimal Residual Disease (MRD)

PRODUCTS

Minimal Residual
Disease
(MRD)

MRD Clonality

Minimal Residual Disease (MRD) is the presence of low levels of malignant cells that remain in a subject during or after treatment or when the patient is in remission. Detectable levels of cancer cells following treatment may suggest a higher probability of relapse.

MRD Clonality

Minimal Residual Disease (MRD) is the presence of low levels of malignant cells that remain in a subject during or after treatment or when the patient is in remission. Detectable levels of cancer cells following treatment may suggest a higher probability of relapse.
WHY IT MATTERS

MRD Clonality testing can save lives.

Residual leukemic cells that remain in the bone marrow following treatment are a major cause of disease relapse and can also act as an early indicator to the effectiveness of a given treatment strategy. Recent treatment advances have led to significantly increased clinical response and overall survival, but ultimately most subjects will relapse, driving the need for sensitive MRD monitoring.
Early detection of disease evolution or recurrence typically provides the highest probability of eradicating cancer. Studies have found that the level of MRD clonality found in bone marrow or peripheral blood samples correlate with the probability of disease recurrence.1 MRD negativity may offer significantly improved clinical outcomes and has been found to be more predictive of overall survival than complete response (CR). Sensitive and standardized testing such as NGS-based MRD may one day enable identification of those cases that will eventually relapse versus those who are potentially cured.
WHEN TO TEST FOR MRD CLONALITY

Following initial induction, it becomes imperative to continuously monitor and accurately trend disease burden.

NCCN guidelines suggest that MRD testing may be used to assess the effectiveness of treatment and to monitor for reccurence of malignant clonotypes during remission. MRD can also help detect refractory cancer when multiple clonotype sequences are tracked.
Increasingly, MRD can be used not only to monitor tumor burden in subjects, but as a surrogate endpoint for clinical trials because it can help standardize testing, collapse timelines and significantly expedite drug approvals.
MRD TEST METHODS

Traditional methods of monitoring MRD include allele specific oligonucleotide polymerase chain reaction (ASO-PCR) and flow cytometry.

Unfortunately, ASO-PCR based MRD testing requires custom primer sets, which increase turn-around-times and are nearly impossible to standardize. Typically, multiparameter flow cytometry is used for MRD clonality testing because it can provide good sensitivity, is inexpensive, and can be used to track multiple immunophenotypes.
Current flow cytometry-based MRD methods are highly subjective and recommendations are often based on consensus expert-shared knowledge and experience, not on a validated, objective method. In addition to the need for standardized methods, new studies suggest that more sensitive methods are needed to better predict outcomes. NGS-based MRD clonality testing offers many benefits over traditional methods as it is very sensitive, easy to standardize, and can be used to track multiple clonotyes simultaneously.

1. Capana, Dario et al. Blood (2012) 120:5172-5180.

Invivoscribe Solutions

LymphoTrack® MRD Bundled Solution

NGS Assays for MRD Testing

MRD testing by Next-Generation Sequencing (NGS) offers enhanced sensitivity and specificity, allowing investigators to monitor and track residual disease through the entire course of a study. Invivoscribe offers state-of-the-art NGS-based Lymphotrack Clonality Assays* and bioinformatics software designed for the study of MRD in IGHIGK, TRG and TRB gene targets.

The Invivoscribe® LymphoTrack®  MRD Bundled Solution* allows researchers to accurately detect and trend clonal evolution in longitudinal studies in their own laboratories, with unprecedented simplicity.

The RUO B-cell MRD Bundle includes:

NOTE: This is only a representative graph that will be included in the upcoming software version.

Contact our sales team at sales@invivoscribe.com or fill out our customer service inquiry form here to learn more about our MRD solutions for B- and T-cell clonality tracking.

*MRD testing with the LymphoTrack MRD Bundled Solution with includes LymphoTrack® Low Positive Control, LymphoQuant® Internal Control and LymphoTrack® MRD Software are for Research Use Only (RUO). Not for use in diagnostic procedures.